Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
INTRODUCTION
Alkylating agents, including the chloroethylnitrosoureas (carmustine [BCNU] , lomustine [CCNU] , and fotemustine), procarbazine, and temozolomide, are commonly used to treat malignant brain tumors. These agents cause DNA damage by adding alkyl groups to DNA, which triggers DNA repair, thereby inducing apoptosis. Temozolomide is a methylating agent that modifies the DNA at several sites, most commonly N 7 -methylguanine and N 3 -methyladenine, which constitute nearly 90% of the total methylation events. 1 However, these adducts are efficiently repaired by the base excision repair pathway and have a low cytotoxic potential. Only 5% to 10% of the methylation events mediated by temozolomide yield O 6 -methylguanine, but if the methyl group
is not removed before cell division, these adducts trigger the DNA mismatch repair (MMR) pathway and are highly cytotoxic. neutralizing the cytotoxic effects of alkylating agents such as temozolomide. The protective effect of MGMT activity against the cytotoxic effects of alkylating agents has been demonstrated in human cell lines, xenograft models, and MGMT transgenic mice. [4] [5] [6] [7] [8] [9] High levels of MGMT activity in tumor tissue are associated with resistance to alkylating agents. 7 In contrast, epigenetic silencing of the MGMT gene by promoter methylation results in decreased MGMT expression in tumor cells. 10, 11 Methylation of the MGMT promoter has been observed in a variety of tumor types, 12 which is consistent with the observation that epigenetic "silencing" of genes is a common mechanism for inactivating tumor suppressor genes during malignant progression. 13, 14 Herein, we review the role of MGMT in conferring resistance to alkylating agents and strategies to modulate MGMT activity in malignant gliomas.
THE ROLE OF MGMT IN RESISTANCE TO ALKYLATING CHEMOTHERAPY
-methylguanine methyltransferase is ubiquitously expressed in normal human tissues. 15 Most of our knowledge about MGMT as a DNA repair protein is based on observations following exposure to alkylating agents. 5 In several ways, the MGMT-mediated repair process (Fig 1) is unique and differs from other DNA repair pathways; MGMT is not part of a repair complex but acts alone. It specifically removes the methyl group from the O 6 position of guanine, thereby restoring the nucleotide to its native form without causing any DNA strand breaks, and it is a "suicide enzyme." On transfer of the alkyl group to an internal cysteine residue in the active site of MGMT, the enzyme is irreversibly inactivated, thus requiring de novo protein synthesis to maintain enzyme activity. In fact, the process is saturable; an excess of O 6 -methylguanine in the DNA can deplete MGMT. Although the O 6 position of guanine is not the most common target of alkylating agents, the resulting promutagenic lesions act as an important trigger for cytotoxicity and apoptosis. 16 Left unrepaired, this modified guanine preferentially pairs with thymine during DNA replication, which activates the MMR pathway. However, MMR only targets and corrects the newly synthesized daughter strand, leaving behind the O 6 -methylguanine in the template strand. It has been hypothesized that the MMR pathway, in an attempt to repair this mismatch, undergoes reiterative cycles of resynthesis and attempted repair (ie, futile cycling). This results in DNA double-strand breaks, thereby activating apoptotic pathways leading to cell death. 17, 18 The essential role of the MMR pathway is illustrated by studies showing that cells deficient in both MGMT and the MMR pathway are 100 times more resistant to methylating agents. 19 It has also recently been shown that treatment of glioblastoma (GBM) with temozolomide seems to select for inactivation of MMR as a result of mutation or loss of expression of the MMRassociated protein MSH6. 20 Consequently, the highest therapeutic activity of alkylating agents is expected in tumor cells with low levels of MGMT and an intact MMR system. 5 Given the central role of MGMT in resistance to alkylating agents and its unique properties, MGMT is an ideal potential target for biochemical modulation of drug resistance.
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Analytic Determination of MGMT
Several methods for measuring MGMT levels within tumors have been described. The
MGMT protein can be detected in tissue samples by immunohistochemistry, 24 enzyme activity can be measured by high-performance liquid chromatography (HPLC), 25, 26 and epigenetic silencing of the MGMT gene by promoter methylation can be assessed using a methylationspecific polymerase chain reaction assay (MSP). 27, 28 Determination of MGMT activity by HPLC requires fresh tissue and is most suitable for quantitative studies in pure populations of cells. 25, 26 Immunohistochemical analysis has revealed heterogeneous MGMT expression patterns within tumors, often with regions of intense staining bounded by adjacent cells that lack expression. 24, 29, 30 Tumor-infiltrating lymphocytes, microglia, and blood vessels may also express high levels of MGMT protein (Fig 2) . Both HPLC and immunohistochemistry have been used to study the correlation between MGMT activity and drug resistance in cell lines and xenografts derived from a variety of human tumors. 31 These studies have shown that MGMT expression varies widely in different tumor types and cell lines.
The MSP assay has been developed for determining the MGMT methylation status of CpG islands in the gene promoter (Fig 3) . 28, 32 The MSP assay detects CpG island methylation with high sensitivity and specificity. This assay requires only small quantities of DNA and can be performed on DNA extracted from paraffin-embedded tissue samples; however, fixation may cause deterioration of the DNA. Therefore, best results are obtained with cryopreserved tumor specimens.
For diagnostic purposes in patients with glioma, one advantage of the MSP assay lies in the fact that detection of the methylated MGMT allele can be attributed solely to neoplastic cells. 33 Therefore, nontumor tissue contamination of the surgical specimen does not interfere with the result. Furthermore, MGMT gene expression may be induced in tumor cells in response to DNA damage from alkylating agents or radiotherapy (RT) and also by corticosteroids, 6, 34 although this remains to be demonstrated in primary gliomas. Aberrant methylation of CpGs is a heritable change in the DNA that may be less susceptible to treatment-induced alterations.
Recent reports have reviewed and discussed the different techniques for assessing MGMT and whether they can predict clinical outcome in glioma patients. [35] [36] [37] The correlation with outcome was variable throughout the studies analyzed, regardless of the techniques employed; however, the overall interpretation of these results is limited because much of the data come from small series or cohorts of mixed glioma subtypes, use of different cut-offs (eg, for immunohistochemistry), and heterogeneity of treatment or complete lack of treatment information. The latter is highly relevant, since MGMT status is thought to predict benefit primarily from treatment with alkylating agents. 32, 38 Clearly, the methods useful for diagnostic purposes will have to be standardized and validated in prospective studies.
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MGMT Expression/Methylation and Clinical Outcome in Malignant Glioma
Clinical studies have correlated MGMT expression or MGMT promoter methylation with response to chloroethylnitrosoureas and methylating agents and with survival. [41] [42] [43] [44] [45] [46] A Southwest Oncology Group study found that MGMT expression levels in newly diagnosed malignant astrocytoma assessed by quantitative immunofluorescence were inversely correlated with tumor response and survival in patients treated with BCNU. 43 The difference in median survival among patients with tumors showing high (n = 41) versus low (n = 23) MGMT expression levels was significant (8 versus 29 months, respectively; P = .0002; Fig 4) . 43 In a retrospective analysis of Similarly, in a phase II trial, we demonstrated significantly improved clinical outcome in patients with newly diagnosed GBM who had a methylated MGMT promoter and were treated with temozolomide and RT. 47 The 18-month survival rate was 62% among patients with a methylated
MGMT promoter compared with only 8% in the absence of promoter methylation (P = .002).
These studies identified MGMT promoter methylation status as a potential independent prognostic factor for survival in GBM patients treated with alkylating agents. Furthermore, Paz et al 44 showed that MGMT promoter methylation was associated with a higher rate of clinical response in patients with primary glioma treated with temozolomide or other alkylating agents (Table 1 ). However, this association was not observed when patients were treated with alkylating agents at relapse, suggesting that selection for treatment resistance had occurred. concomitant and adjuvant temozolomide. 32 Paraffin-embedded tissue samples were available for 307 (54%) patients. High-quality DNA, allowing for analysis by MSP assay, could be extracted from two thirds of the available tissue, and 45% of this group were shown to have a methylated MGMT promoter. The MSP assay consisted of a 2-stage polymerase chain reaction using nested primers. 48 The results showed that MGMT promoter methylation was associated with improved overall survival in patients treated with RT plus temozolomide but not in patients initially treated with RT alone (Fig 5) . 32 Among patients whose tumors contained a methylated MGMT promoter, patients treated with RT plus temozolomide had a median survival of 21.7 months compared with 15.3 months for patients assigned to RT alone. In patients treated with initial RT alone, MGMT promoter methylation was also associated with a slight improvement in survival among patients surviving beyond 9 months. This was expected because more than 70% of the patients in the RT arm received chemotherapy (most likely with an alkylating agent)
at progression, and 60% of these patients received temozolomide at progression. When progression-free survival (PFS) was analyzed, thereby eliminating second-line therapy as a confounding factor, PFS was only prolonged in patients with a methylated MGMT promoter who were treated with RT plus temozolomide (Fig 6) . 32 In patients with a methylated MGMT promoter, median PFS was 10.3 months for patients treated with RT plus temozolomide compared with 5.9 months in the RT-only group (P = .001).
CLINICAL STUDIES OF TEMOZOLOMIDE AND MGMT INHIBITORS
Given -BG 18 hours before surgery (Table 2) . Although this analysis did not take into account that MGMT activity may have been constitutively low due to promoter methylation in 30% to 50% of patients, these data suggest either that O 6 -BG is only able to transiently inhibit the enzyme or that resynthesis of MGMT can occur rapidly in tumor tissue. 51 No toxic side effects were observed in this study. Importantly, this study illustrated how transient the reduction in MGMT activity may be with such a treatment approach.
Other studies have attempted to determine the maximum tolerated dose of [63] [64] [65] Subsequent clinical trials with temozolomide have explored a variety of dosing schedules (Table 3 ) with the intention of maximizing MGMT depletion in tumor cells. The first alternative regimen tested was the extended daily regimen, 58 which was subsequently used in combination with RT in the trials conducted by the EORTC. These regimens increase exposure to temozolomide over a 28-day cycle by approximately 1.5-to 2-fold compared with the standard 5-day regimen, and the hope is that these alternative regimens will increase antitumor activity compared with the 5-day regimen without dramatically increasing hematologic toxicity.
However, to date, there is no empiric evidence that this can be achieved in clinical practice.
This concept of enhanced MGMT depletion with alternative temozolomide dosing regimens has been rigorously tested by Tolcher et al. 66 Patients received temozolomide at various doses and on 2 alternative dosing schedules: either 7 consecutive days of every 14 days (7 days on/7 days off) or 21 consecutive days of every 28 days (21/28-day schedule).
Serial blood samples were taken to assess MGMT enzyme activity in PBMCs. This study demonstrated a time-and dose-dependent decrease in MGMT activity with both regimens.
Continuous dosing for 7 days at a dose of 75 to 175 mg/m 2 produced a rapid reduction from mean baseline MGMT activity (72% on day 8), which appeared to be fairly dose dependent.
However, during the 7-day rest period, there was recovery of MGMT activity to approximately 55% of baseline (Fig 7) . 66 The 21-day continuous schedule at a lower daily dose (85 to 125 mg/m 2 ) resulted in a similar reduction (~70%) in mean MGMT activity by day 15, which was sustained through day 21.
This study established a benchmark against which to evaluate alternative dosing regimens and illustrated several important concepts with regard to MGMT depletion with temozolomide. The depletion of MGMT activity was a function of both the total cumulative dose and the area under the concentration time curve. 66 The daily and cumulative doses administered using a variety of dose-dense regimens are shown in Table 3 . Higher doses of temozolomide appear to deplete MGMT levels in PBMCs more rapidly than lower doses.
Administration of temozolomide for 21 consecutive days at a daily dose that resulted in a comparable cumulative dose per cycle as the 7-days-on/7-days-off regimen resulted in comparable depletion of MGMT activity at lower daily doses. However, this regimen appears to achieve more protracted MGMT depletion at least in PBMCs. On the other hand, the 7-days-on/7-days-off regimen allows for better recovery of MGMT in PBMCs, which may result in less hematologic toxicity.
Currently, it is not known which of these schedules is more effective at depleting MGMT in tumor cells or which will strike a better balance between antitumor activity and hematologic toxicity. Although the Tolcher study provides the best rationale for protracted temozolomide schedules, there remain a number of important unanswered questions. In particular, it remains unknown how these schedules affect MGMT activity in brain tumor tissue. Studies reported by Spiro et al 26, 61 suggest that depletion of MGMT activity in PBMCs occurs at lower doses of
-BG or temozolomide and is not a reliable predictor of MGMT depletion in tumor tissue.
BRAIN TUMOR TRIALS WITH NOVEL SCHEDULES OF TEMOZOLOMIDE
A number of studies in patients with high-grade glioma have investigated alternative temozolomide dosing schedules and have begun to look at important clinical questions with regard to the best treatment strategy in both the first-line and recurrent settings (Table 4) . [67] [68] [69] [70] [71] [72] [73] [74] One particularly relevant question is whether concomitant RT plus temozolomide is sufficient to confer a survival benefit in patients with newly diagnosed GBM. This question is the object of an ongoing international Intergroup trial designed to establish the optimal sequence and relative contribution of the concomitant and adjuvant chemotherapy compared with RT alone in patients with anaplastic astrocytoma. Over 700 patients will be randomized in the
CATNON trial (Concurrent and Adjuvant Temozolomide in NON-deleted anaplastic astrocytoma).
One study in Greece has examined whether dose intensification of the maintenance regimen affects clinical outcome. In a randomized multicenter phase II trial patients with newly diagnosed GBM received the standard regimen of concomitant RT plus temozolomide followed by temozolomide at a dose of 150 mg/m 2 x 5 days every other week compared with RT alone. 67 The results suggested that this dose-intensified maintenance regimen may improve PFS in the absence of significant hematologic toxicity. 67 Patients treated with RT plus temozolomide had a median PFS of nearly 11 months, and 37% of patients had not yet progressed at 1 year. This was substantially better than the PFS achieved with RT plus temozolomide in the EORTC/NCIC trial (median of 7 months, and 1-year PFS of 27%). 75 However, this improvement in PFS did not appear to translate into a substantial improvement in overall survival; median overall survival was 13.4 months with RT plus temozolomide (compared with 14.6 months in the EORTC/NCIC trial 75 ) and only 7.7 months in the RT-only arm. 67 Although patient selection cannot be ruled out, the poor survival outcome, particularly in the control arm, may have been due to the small number of patients who received chemotherapy at recurrence. Nevertheless, this trial provides evidence of the safety and feasibility of a dose-intensified temozolomide maintenance regimen.
A French phase II study also examined the effect of the 7-days-on/7-days-off regimen (150 mg/m 2 /day) as both neoadjuvant therapy before RT for up to 4 cycles (8 weeks) and adjuvant (ie, maintenance) therapy after RT until progression (up to 8 cycles) in patients with inoperable tumors. 76 This study provided information about antitumor activity in the neoadjuvant setting, although the median number of cycles was only 3 (range, 1 to 8).
Consistent with the previous attempts at neoadjuvant therapy for GBM, 25% of patients had a partial response, and 31% had stable disease. Median PFS in this group of patients with poor prognosis was 3.8 months, and median overall survival was 6 months. Hematologic toxicity requires careful monitoring; 24% of patients developed grade 3 or 4 thrombocytopenia, 14%
had grade 4 granulocytopenia, and 14% had grade 4 lymphopenia. In addition, 5 patients developed interstitial pneumopathy, and 6 patients required dose reductions. This study also provided evidence that MGMT expression correlated with response to temozolomide; despite dose intensification, patients with high levels of MGMT expression in their tumor tissue were unlikely to respond and more likely to progress early.
To date, the largest clinical experience with an alternative temozolomide regimen in the first-line setting is from the joint German-Swiss randomized phase III trial of the Neuro-oncology Working Group within the German Cancer Society (NOA-08). 71 This trial is currently investigating the benefit of temozolomide (100 mg/m 2 7 days on/7 days off) versus RT alone as a primary therapy for high-grade glioma until treatment failure and shall enroll 340 patients over the age of 65 years.
In the recurrent setting, several studies have investigated dose-dense regimens. Italian investigators studying temozolomide at 75 mg/m 2 on a 21/28-day schedule reported grade 3 lymphocytopenia in one fourth of patients and an increased incidence of infections. 72, 77 In our previous experience with temozolomide administered at 75 mg/m 2 for 6-7 weeks concurrent with RT, up to 80% of patients developed profound lymphocytopenia, further promoted by the frequent administration of corticosteroids at diagnosis. 63 A small Belgian phase II trial has also examined the 21/28-day schedule at a dose of 100 mg/m 2 in 19 patients with recurrent anaplastic astrocytoma and anaplastic oligoastrocytoma. 73 A report on the safety profile of this regimen indicated a high incidence of grade 3 and 4 lymphopenia in 10 and 9 patients, respectively. In addition, there were 2 suspected opportunistic infections: 1 herpes zoster reactivation during lymphopenia and 1 case of Pneumocystis carinii pneumonia after the patient had discontinued study treatment. Therefore, it appears that regular lymphocyte counts and prophylaxis against opportunistic infections may be required when using this regimen, particularly in the recurrent setting. Similar observations have been made in melanoma patients who were treated with the daily schedule (75 mg/m 2 × 6 to 7 weeks). 64 The high frequency of lymphopenia in patients receiving prolonged daily schedules of temozolomide raises the question whether more intermittent dosing might be better tolerated. The most compelling data come from a German study in 39 patients with recurrent GBM who were treated with 150 mg/m 2 on the 7-days-on/7-days-off regimen, which was associated with a relatively low incidence of lymphopenia. 69, 70 This regimen produced an overall response rate of 9.5%, a 6-months PFS rate of 48%, and a median PFS of 21 weeks (~5 months), 69 which is superior to the data reported on the standard 5-day dosing regimen. 78 These data have since been confirmed and extended. 74 Importantly, in the more recent trial involving 90 patients, there was no significant difference in median PFS between patients with a methylated or unmethylated MGMT promoter at initial diagnosis. 74 This suggests either that patients with a methylated MGMT promoter at diagnosis acquired resistance to temozolomide during progression 20, 44 or that this regimen may indeed overcome MGMT-mediated resistance, thereby extending time to progression in patients with an unmethylated promoter.
CONCLUSIONS AND FUTURE DIRECTIONS
A variety of molecular markers may have prognostic value in patients with malignant glioma. These markers include high expression of MGMT, overexpression of the epidermal growth factor receptor (EGFR), presence of the EGFRvIII mutation, expression of the YKL-40
gene, tenascin expression, loss or mutation of the PTEN gene, loss of chromosome 10, and mutation or loss of the p53 gene. [79] [80] [81] [82] Although MGMT expression appears to have a strong influence on response to alkylating agents and clinical outcome in patients with GBM, to date none of these markers, including MGMT, has been definitively confirmed.
An international group of investigators from the United States, Canada, and Europe is collaborating on a successor clinical trial to the EORTC/NCIC study. This trial, RTOG 0525, led by the Radiation Therapy Oncology Group Intergroup (RTOG) along with the EORTC and the North Central Cancer Treatment Group, will test whether increasing the dose intensity of adjuvant temozolomide will improve survival compared with the standard regimen established by the EORTC/NCIC study. 83, 84 The study design is shown in Fig 8. 83, 84 The underlying hypothesis for this phase III trial is based on the laboratory finding that prolonged exposure of tumor cells to temozolomide results in reduced MGMT activity. 85 An accrual of 1,153 patients is expected, and both clinical and molecular markers are being used to assign patients to the two treatment arms. Clinical factors include the validated subgroups identified by the recursive partitioning analysis of the RTOG, and patients in classes III, IV, and V are eligible for study entry. In addition, immediate tumor tissue sample submission is mandatory to prospectively assess MGMT promoter methylation status (using a quantitative MSP assay), and patients are then stratified by MGMT promoter methylation status before randomization. This will ensure a balanced number of patients with MGMT-methylated tumors assigned to the control and experimental arms, which will be critical for validation of MGMT promoter methylation as a molecular marker of response and/or prognosis.
GBM patients treated with temozolomide, it is presently not recommended to use the MGMT promoter methylation assay to determine who should receive temozolomide and who should not. 37 First, an independent confirmation of the retrospective analysis from the EORTC/NCIC trial is necessary. Second, there is reason to believe that alternative dose-intensified schedules may overcome resistance in patients with an unmethylated MGMT promoter. 86 Third, allocating GBM patients to specific treatments on the basis of MGMT promoter methylation status will only assume clinical relevance when effective alternative treatments become available. At present, the only established alternative is nitrosourea-based chemotherapy, which is also subject to resistance mediated by MGMT.
A promising strategy to overcome resistance mediated by MGMT appears to be depletion of MGMT by prolonged exposure to low doses of alkylating agents. For these agents, The MGMT enzyme transfers the methyl group from the O 6 -methylguanine DNA adduct to a cysteine residue in the enzyme and becomes irreversibly inactivated. 
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